Case Report: Durable remission in stage IV melanoma following strategic immune checkpoint inhibitor class rotation and rechallenge - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Case Study: Sustained Remission in Advanced Melanoma After Strategic Rotation and Rechallenge of Immune Checkpoint Inhibitors

  • By

  • Jamila Raja

  • Shuo Li

  • Asal Patterson

  • Steve R. Martinez

  • Perry A. Soriano

  • Xiaowen Wang

  • Peter Y. Z. Jiang

  • July 16, 2026

Share

Clinical Scorecard: Case Study: Sustained Remission in Advanced Melanoma After Strategic Rotation and Rechallenge of Immune Checkpoint Inhibitors

At a Glance

CategoryDetail
ConditionAdvanced Melanoma
Key MechanismsCTLA-4 blockade and PD-1 blockade
Target PopulationPatients with advanced melanoma and severe immune-related adverse events
Care SettingOncology

Key Highlights

  • Patient achieved complete remission after ICI rechallenge.
  • Severe irAEs occurred during initial Nivolumab therapy.
  • Strategic rotation to Ipilimumab followed by Nivolumab rechallenge was utilized.
  • Patient remained disease-free for nearly five years post-treatment.
  • No recurrence of prior irAEs after rechallenge.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of advanced melanoma confirmed through imaging and biopsy.

Management

  • Consider rotation of ICI agents after severe irAEs.

Monitoring & Follow-up

  • Regular surveillance imaging for disease progression.

Risks

  • Severe immune-related adverse events may necessitate treatment discontinuation.

Patient & Prescribing Data

59-year-old male with advanced nodular melanoma.

Rechallenge with Nivolumab after Ipilimumab resulted in complete remission.

Clinical Best Practices

  • Individualized risk-benefit assessment for ICI rechallenge.
  • Management of irAEs with immunosuppressive therapy.

Related Resources & Content

Original Source(s)

Case Report: Durable remission in stage IV melanoma following strategic immune checkpoint inhibitor class rotation and rechallenge

  • by Jamila Raja, Shuo Li, Asal Patterson, Steve R. Martinez, Perry A. Soriano, Xiaowen Wang, Peter Y. Z. Jiang

  • July 16, 2026

Related Content

Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.

  • June 24, 2026

  • 1 min
Medically Assisted Reproduction and Hormone-Related Cancers

The Rise in Homemade Sunscreen Trends and Future Impacts on Skin Cancer Risk: Systematic Review